Breakthrough for medical science! England approves world's first 7-minute cancer treatment injection

Breakthrough for medical science! England approves world's first 7-minute cancer treatment injection

It boosts the patient's immune system to identify and eliminate cancer cells.

Britain's government National Health Service will be the first in the world to offer a cancer-treating injection to hundreds of patients in England, which could cut treatment times by up to three-quarters.

Following approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), NHS England said on Tuesday (29 August) that hundreds of eligible patients being treated with the immunotherapy, atezolizumab, would be injected "under the skin", which would free up more cancer cells. Teams time.

Atezolizumab is usually given intravenously to patients through an IV drip, but many of them will now be given immunotherapy via injection.

The drug, also known as Techentric, treats a variety of cancers, including lung, breast, liver and bladder cancer. It is given to about 3,600 patients in England each year.

Dr Alexander Martin, consultant oncologist at West Suffolk NHS Foundation Trust, said: "This approval will not only allow us to provide more convenient and faster care for our patients, but will also enable our teams to treat more patients throughout the day. " Reuters.

Manufactured by Genentech, a subsidiary of Roche Company, this immunotherapy drug boosts a patient's immune system to identify and eliminate cancer cells. This therapy is currently given via transfusion to NHS patients with a variety of cancers, such as lung, breast, liver and bladder cancer.

NHS England said negotiations on an existing commercial deal with manufacturer Roche resulted in faster treatment at no extra cost.

Roche's medical director, Marius Scholtz, said: “Injecting Texentric under the skin offers a faster treatment option as it takes about seven minutes, whereas the current method of intravenous infusion of Texentric takes 30 to 60 minutes.

"We are delighted that NHS patients across England have access to subcutaneous PD-L1 cancer immunotherapy injections."